1/2
"#Lenacapavir, a twice-yearly, long-acting #HIV prevention tool, represents one of the most promising advances towards ending #AIDS [.]. #Gilead has an obligation to ensure that access is not restricted by where people live, who they are, or what their country can pay. [.] this drug’s development was supported by public funding and through the trust of communities who participated in clinical trials, many of them in countries now excluded from affordable access [.]."

https://www.doctorswithoutborders.org/latest/prevention-should-not-be-privilege-msf-calls-gilead-direct-access-lenacapavir